ESC 365 - Discussion - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.

ESC Premium Access

Discussion - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.

Session: Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)

Topic: Diabetes and the Heart

Speaker: Professor F. Cosentino (Stockholm, SE)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim/Lilly

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Francesco Cosentino

Karolinska University Hospital, Stockholm (Sweden)

26 presentations

1 follower

4 more presentations in this session

Introduction - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.

Speaker: Professor F. Cosentino (Stockholm, SE)

SGLT2 inhibition in cardiology: what is the profile of benefit? .

Speaker: Professor N. Marx (Aachen, DE)

Changing focus in diabetes: From glucose to cardiovascular risk management.

Speaker: Professor S. Jacob (Villingen, DE)

Heart failure & SGLT2: with or without diabetes?

Speaker: Professor J. McMurray (Glasgow, GB)

Access the full session

Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)

Speakers: Professor F. Cosentino, Professor F. Cosentino, Professor N. Marx, Professor S. Jacob, Professor J. McMurray

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources